AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15104658
Drug: Remobilization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remobilization with DXM 1.5 mg
Trial: 9781831
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aspirin/day
Trial: 9781831
Drug: Aspirin (30-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30-300 mg/day)
Trial: 17974384
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.25 mcg/day 1‐alpha‐OHD3 plus 10 mcg/day 24,25(OH)2D3
Trial: 2681316
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 1.0 mg/kg
Trial: 26152411
Drug: Fluralaner (Bravecto)
RxNorm normalized name: fluralaner Topical Solution [Bravecto]
DrugBank: Fluralaner (DB11414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner (Bravecto) (dosage 25.1 - 49.4 mg/kg)
Trial: 19735513
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol (HF) chocolate, 20 g daily for 12 weeks
Trial: 19735513
Drug: Low flavanol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanol (LF) chocolate, 20 g daily for 12 weeks
Trial: 17023228
Drug: Controlled-release carvedilol
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release carvedilol (CR) 20 mg once daily
Trial: 17023228
Drug: Immediate-release carvedilol
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carvedilol (IR) 6.25 mg twice daily
Trial: 17023228
Drug: Controlled-release carvedilol
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release carvedilol (CR) 80 mg once daily
Trial: 17023228
Drug: Immediate-release carvedilol
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carvedilol (IR) 25 mg twice daily
Trial: 17023228
Drug: Controlled-release carvedilol
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release carvedilol (CR)
Trial: 17023228
Drug: Immediate-release carvedilol
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carvedilol (IR)
Trial: 10357953
Drug: recombinant follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle stimulating hormone (rFSH)
Trial: 10357953
Drug: urinary follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urinary follicle stimulating hormone (uFSH)
Trial: 1904183
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg thrice daily for 4 weeks postoperatively
Trial: 23486755
Drug: Cognitive-behavioral training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral training and automated phone calls (6 sessions, 90 mins each, weekly; phone calls twice daily for 1 year)
Trial: 24429855
Drug: Preoperative antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antiseptic treatment of the operative field
Trial: 18492760
Drug: Preoperative octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative octreotide treatment (20 mg im every 28th day for 6 months)
Trial: 18492760
Drug: Preoperative octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative octreotide treatment (20 mg im every 28th day for 6 months) in patients with macroadenomas
Trial: 12975720
Drug: [(14)C]M100240 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(14)C]M100240 (25 mg, 50 microCi) as an oral solution under fasting conditions
Trial: 27454273
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 5 µg of dexmedetomidine (group I)
Trial: 27454273
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 0.1 mg/kg ketamine (group II)
Trial: 27454273
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of hyperbaric bupivacaine 0.5%, 5 µg of dexmedetomidine, and 0.1 mg/kg of ketamine (group III)
Trial: 20088937
Drug: Avidin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avidin (100 mg)
Trial: 18397971
Drug: Medication Event
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication Event Monitoring System (MEMS) used daily
Trial: 16521844
Drug: GEL (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (1.1 +/- 0.2 g/kg body mass carbohydrate)
Trial: 16521844
Drug: PLACEBO (flavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO (flavored placebo drink, 426 +/- 227 mL)
Trial: 10579151
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg orally once daily for 14 days
Trial: 10579151
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg oral dose
Trial: 8610720
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (500 microgram) + metaproterenol sulfate (15 mg)
Trial: 8610720
Drug: Metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol sulfate (15 mg)
Trial: 2998440
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with 10 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Trial: 2998440
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with 16 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Trial: 2998440
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with 30 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Trial: 2998440
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with no bran, but phytate and Zn added equivalent to 10 g bran
Trial: 23452436
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab with last acuity of drop-outs carried forward
Trial: 23452436
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab in late phase
Trial: 23452436
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab in early phase
Trial: 20103782
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) - 6 mg/m² every 4 weeks for 3 cycles
Trial: 20103782
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - no postremission therapy
Trial: 18051017
Drug: Family Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Focused Grief Therapy
Trial: 16191743
Drug: D2 dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2 dopamine receptor TaqI A polymorphism
Trial: 11945097
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 800 mg/day
Trial: 1888345
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (stimulus control/relaxation training)
Trial: 30400939
Drug: Weekly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly high-dose recombinant human erythropoietin (EPO) 40,000 IU/mL for 12 weeks
Trial: 30400939
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) infusions for 12 weeks
Trial: 24715364
Drug: Clozapine plasma
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine plasma levels (Clz pl≥300μg/L)
Trial: 24715364
Drug: Clozapine plasma
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine plasma levels (Clz pl<300μg/L)
Trial: 15793941
Drug: Pneumococcal seven-valent
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal seven-valent conjugate vaccine (Prevenar)
Trial: 11607795
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg or Enalapril 20 mg (for patients ≤40 years); Amlodipine 10 mg + Atenolol 50 mg or Enalapril 20 mg + Hydrochlorothiazide 25 mg (for patients >40 years)
Trial: 9893735
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg twice a day
Trial: 9893735
Drug: L-NMMA (0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (0.75, 1.5, and 3.0 mg/kg/h)
Trial: 8281874
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg four times a day
Trial: 7223302
Drug: Albumin therapy
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin therapy (60-75 g postoperatively)
Trial: 7223302
Drug: Albumin therapy
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin therapy and Control
Trial: 30185291
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist intervention (e.g., medication dose adjustment, initiation, or discontinuation)
Trial: 30185291
Drug: Factors predictive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors predictive of requiring an intervention (e.g., clopidogrel dispensing, fall, vertebral fracture diagnosis)
Trial: 17660026
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF), 1 g twice daily for 12 months
Trial: 17660026
Drug: Cyclophosphamide, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, 1.5 mg/kg/d for 12 months
Trial: 11799102
Drug: Aliskiren 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 40 mg/d
Trial: 11799102
Drug: Aliskiren 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 80 mg/d
Trial: 11799102
Drug: Aliskiren 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 160 mg/d
Trial: 10320183
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream (EMLA; Astra, Sweden) for 1 hour postburn
Trial: 10320183
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream for 1 hour postburn
Trial: 8542174
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for colorectal cancer
Trial: 1961137
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg midazolam HCl
Trial: 31958286
Drug: First-line EGFR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line EGFR inhibitors
Trial: 31073879
Drug: Group-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-Based Cognitive Behavioral Therapy (CBT), 12 sessions
Trial: 16266457
Drug: 500 micromol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micromol/L Hcy
Trial: 16266457
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid with 500 micromol/L Hcy
Trial: 10428146
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg once daily for 12 months
Trial: 10428146
Drug: Flutamide 250
RxNorm normalized name: flutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 250 mg twice daily for 12 months
Trial: 2097149
Drug: CAP (C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP (C = 600 mg/sqm, A = 45 mg/sqm, P = 50 mg/sqm)
Trial: 2097149
Drug: CA (C
RxNorm normalized name: COFFEA ARABICA (COFFEE) SEED OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA (C = 600 mg/sqm, A = 45 mg/sqm)
Trial: 31797578
Drug: Filgotinib 450
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filgotinib 450 mg
Trial: 16041547
Drug: Rifampin 300
RxNorm normalized name: rifampin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 300 mg daily (n=6)
Trial: 16041547
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg daily (n=6)
Trial: 31815653
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course systemic antibiotics (≤ 7 days)
Trial: 31815653
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course systemic antibiotics (≥ 4 weeks)
Trial: 20701024
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg daily, one hour before sleep (group A)
Trial: 20701024
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg daily, one hour before sleep (group B)
Trial: 16639731
Drug: FAC (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (5-fluorouracil 1000 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Trial: 16639731
Drug: FAC followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FAC followed by high-dose chemotherapy (HDCT) with autologous stem cell support (ASCS) (high-dose cyclophosphamide 5250 mg/m2, etoposide 1200 mg/m2, cisplatin 165 mg/m2)
Trial: 8908525
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (Group 1, n = 48)
Trial: 8908525
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 100 mg daily for the first 10 days of a 21-day cycle with an oral contraceptive containing 2 mg cyproterone acetate (Group 2, n = 65)
Trial: 8908525
Drug: Spironolactone (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100-200 mg daily) (Group 3, n = 12)
Trial: 8908525
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg daily) (Group 4, n = 16)
Trial: 8908525
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (Group 1)
Trial: 6761087
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment with 200-mg clotrimazole suppositories
Trial: 6761087
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment with 100-mg clotrimazole suppositories
Trial: 6761087
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with miconazole or clotrimazole
Trial: 31060740
Drug: Ambrisentan/Tadalafil fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan/Tadalafil fixed-dose combination (10 mg ambrisentan + 40 mg tadalafil)
Trial: 31060740
Drug: Ambrisentan/Tadalafil fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan/Tadalafil fixed-dose combination (5 mg/20 mg)
Trial: 31060740
Drug: Ambrisentan/Tadalafil fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan/Tadalafil fixed-dose combination (5 mg/40 mg)
Trial: 9932217
Drug: 5-day structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day structured treatment and teaching programme (DTTP) for intensified insulin therapy
Trial: 7829634
Drug: GH (Humatrope,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (Humatrope, Eli Lilly; 0.074 mg/kg, sc, 3 times/week; n = 9)
Trial: 2574986
Drug: Extradural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural diamorphine 0.1 mg kg‐1
Trial: 2574986
Drug: Extradural somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural somatostatin 3 mg
Trial: 764996
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of acetone-inactivated and dried typhoid vaccine
Trial: 764996
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of acetone-inactivated and dried typhoid vaccine
Trial: 21350423
Drug: Cytoflavin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin and basic treatment (trental and group B vitamins)
Trial: 21350423
Drug: Corticosteroids (metipred)
RxNorm normalized name: Veripred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (metipred) as an add-on in pulse-treatment regime
Trial: 19118069
Drug: Pemetrexed 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 900 mg/m(2) + 75 mg/m(2) cisplatin
Trial: 19118069
Drug: Pemetrexed 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 800 mg/m(2) + 75 mg/m(2) cisplatin
Trial: 19118069
Drug: Pemetrexed (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (various doses)
Trial: 19118069
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m(2) + 75 mg/m(2) cisplatin
Trial: 29530257
Drug: Cognitive Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Preparation + Video Feedback + Audience Feedback + Cognitive Review (CP + VF + AF + CR)
Trial: 29530257
Drug: Cognitive Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Preparation + Video Feedback + Cognitive Review (CP + VF + CR)
Trial: 29530257
Drug: Cognitive Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Preparation + Video Feedback only (CP + VF)
Trial: 16241946
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (2.5 mg b.i.d.)
Trial: 16241946
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (5 mg b.i.d.)
Trial: 16241946
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (10 mg b.i.d.)
Trial: 16241946
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (20 mg b.i.d.)
Trial: 16241946
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (30 mg b.i.d.)
Trial: 16241946
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg b.i.d.)
Trial: 16241946
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (2.5-10 mg b.i.d.)
Trial: 12133066
Drug: Vasal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasal lavage with 50 mL of normal saline
Trial: 2160414
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) injection of CY 216, 100 anti-factor Xa IC U/kg
Trial: 2160414
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection of CY 216, 100 anti-factor Xa IC U/kg
Trial: 31099219
Drug: Medication artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication artificial menstrual cycle method (Femoston)
Trial: 28829526
Drug: Morphine-ADER-IMT 60
RxNorm normalized name: morphine sulfate 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-ADER-IMT 60 mg
Trial: 28829526
Drug: Morphine-ADER-IMT 30
RxNorm normalized name: morphine sulfate 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-ADER-IMT 30 mg
Trial: 28829526
Drug: Morphine-ADER-IMT 2
RxNorm normalized name: morphine sulfate 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-ADER-IMT 2 ȕ 15 mg